For health professionals

Effecol 3350 (Macrogol 3350) is a laxative
trusted by doctors, pharmacists
and patients worldwide

 

level 1 grade of evidence A

Level 1 laxative, Grade of evidence A in the ΗΠΑ1,2

children's constipation

1st choice laxative for both constipation and maintenance therapy3

pregnancy

Laxative of choice in pregnancies according to American Gastroenterological Association4

Parkinson's disease

Laxative of choice in case of chronic constipation in patients with Parkinson’s disease according to the American Academy of Neurology5

1. Bharucha AE, et al, American Gastroenterological Association medical position statement on constipation.Gastroenterology. 2013 Jan;144(1):211-7. 2. Lindberg G. et al, World Gastroenterology Organisation global guideline: Constipation–a global perspective.J Clin Gastroenterol. 2011 Jul;45(6):483-7. 3. M.M. Tabbers, C. DiLorenzo, M.Y. Berger, C. Faure, M.W. Langendam, S. Nurko, A. Staiano, Y. Vandenplas, and M.A. Benninga. Evaluation and Treatment of Functional Constipation in Infants and Children: Evidence-Based Recommendations From ESPGHAN and NASPGHAN. JPGN 2014;58: 258–274. 4. American Gastroenterological Association Institute Technical Review on the Use of Gastrointestinal Medications in Pregnancy. Gastroenterology; 2006;131:283–311. 5. Neurology 2010;74;924-931
Movement Disorders, 26(S3) 42-80, October 2011

Effecol has a
different mode
of action than
stimulant laxatives

Acts by osmotic transport of water
into the intestinal tract6

6. Pavlidis C. Constipation: the correct diagnostic and therapeutic approach. Medical Chronicles of Northern Greece 2013, Vol. 9, Issue 1.

Effecol has a
different mode
of action than
stimulant laxatives

Stimulant laxatives act by affecting the gastrointestinal tract, increasing motility and secretory function of the intestine6

6. Pavlidis C. Constipation: the correct diagnostic and therapeutic approach. Medical Chronicles of Northern Greece 2013, Vol. 9, Issue 1.

logo effecol 3350

 

Clinically proven efficacy

Economic impact of low dose polyethylene glycol 3350 plus electrolytes compared with lactulose in the management of idiopathic constipation in the UK. Christie, AH, et al.UK. Pharmacoeconomics, 2002; 20(1):49-60.
Lee-Robichaud H, Thomas K, Morgan J, Nelson RL. Lactulose versus polyethylene glycol for chronic constipation: review. Cochrane Database Syst Rev. 2010;7:1-38.

· Macrogol 3350(PEG) is superior to lactulose both in efficacy and cost/result ratio.

· The results of the metanalysis study in adults and children with constipation showed that macrogol is superior to lactulose in decreasing abdominal pain, improving frequency of bowel movements and stool quality.

Cleveland MV, Flavin DP, Ruben RA, Epstein RM, Clark GE. New polyethylene glycol laxative for treatment of constipation in adults: a randomized, double-blind, placebo-controlled study. South Med J. 2001;94(5):478-481.

· Patients that received macrogol had significant statsitrical improvement in increasing bowel movements in comparison to those that received the placebo 7.0 vs 3.6 (p<0.001)

DiPalma JA, Cleveland MB, McGowan J, Herrera JL. A comparison of polyethylene glycol laxative and placebo for relief of constipation from constipating medications. South Med J. 2007;100(11):1085-1090.

· Macrogol 3350 prseented greater efficacy from the first week in comparison to placebo patients with drug induced constipation. 78.3 vs 39.1 (p<0.001).